The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment.
 
Shannon Neville Westin
Consulting or Advisory Role - AstraZeneca; BioAscent; Casdin Capital; Clovis Oncology; Genentech; Gerson Lehrman Group; Medivation; Medscape; Merck; Ovation Sciences; Pfizer; Roche; Tesaro; Vaniam Group; Vermillion; Watermark Research Partners
Research Funding - ArQule; AstraZeneca; Bayer; Biomarin; Celgene (I); Clovis Oncology; Cotinga Pharmaceuticals; Critical Outcome Technologies; Karyopharm Therapeutics (I); Kite, a Gilead company (I); Novartis; Roche/Genentech; Tesaro
 
Melinda Louie-Gao
Employment - Tesaro
Stock and Other Ownership Interests - Tesaro
 
Enkhe Badamgarav
Employment - Tesaro
Stock and Other Ownership Interests - Tesaro
 
Mohan V. Bala
Employment - Tesaro
Stock and Other Ownership Interests - Tesaro
 
Premal H. Thaker
Stock and Other Ownership Interests - Celsion
Consulting or Advisory Role - Abbvie/Stemcentrx; Abbvie/Stemcentrx; Celsion; Clovis Oncology; Iovance Biotherapeutics; Stryker; Tesaro; Unleash
Speakers' Bureau - Merck; Tesaro
Research Funding - Merck (Inst)